Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BC006 Antibody Injection in Idiopathic Pulmonary Fibrosis
CTR20260327Phase 2Active
- Sponsor
- Dragon Boat Biopharmaceutical
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of muzastotug in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by Dragon Boat Biopharmaceutical. Started Apr 2026; status: active.
02
Drugs
muzastotug
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on CTR20260327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260327.